— Study focuses on interferon blocker's hematologic and serologic benefits
by John Gever, Contributing Writer, MedPage Today
June 17, 2026
• 3 min read
Anifrolumab (Saphnelo) is approved for patients with systemic lupus erythematosus (SLE) and its efficacy for symptom relief has been demonstrated for up to 4 years.This study focused on anifrolumab's long-term effects on hematologic parameters such as hemoglobin, platelets, and white blood cells, as well as SLE serologic biomarkers, in the drug's clinical trial participants.Findings showed that these biomarkers improved with treatment and these improvements were sustained and, in many cases, increased over 4 years of follow-up.
